Nivolumab (Opdivo): Competitive Landscape and Lifecycle Strategy

Nivolumab, sold as Opdivo, is a PD-1 inhibitor that, alongside pembrolizumab, established immune checkpoint blockade as a pillar of cancer therapy. Its approvals span melanoma, lung, kidney, bladder, head and neck, esophageal, gastric, liver, colorectal (in selected biomarker-defined disease), classical Hodgkin lymphoma and other cancers.

Mechanism at a glance

Nivolumab is a fully human IgG4 antibody against PD-1. As with other checkpoint inhibitors, immune-related adverse events can affect almost any organ and require early recognition and steroid treatment. Dosing schedules include both every-two-weeks and every-four-weeks options for the intravenous form.

Combination strategy

Nivolumab was a pioneer in dual checkpoint blockade, pairing with ipilimumab (CTLA-4) in several tumors. A fixed-dose combination with relatlimab (LAG-3) was developed for melanoma, validating a third checkpoint pathway, although the adjuvant melanoma trial RELATIVITY-098 missed its primary endpoint in February 2025.

Lifecycle management

• Subcutaneous formulation: Opdivo Qvantig, the first subcutaneous PD-1 inhibitor, was approved by the FDA in December 2024 (it is not indicated with ipilimumab), and a subcutaneous nivolumab was approved in the EU in May 2025.
• Perioperative use: studies in the neoadjuvant and adjuvant settings are expanding the earlier-stage opportunity.
• Exclusivity: European patent challenges are advancing, and biosimilar developers including Amgen are running Phase 3 trials.

Competitive questions

1. Where does nivolumab hold an advantage over pembrolizumab, and where does it simply follow?
2. Will LAG-3 and other new pathways add meaningful benefit in tumors beyond melanoma?
3. How will PD-1/VEGF bispecifics and other next-generation designs change the baseline?
4. What is the impact of subcutaneous administration on market share in practice?

For the other leading anti-PD-1, see the pembrolizumab landscape.

Recent developments

Updated October 8, 2026. Items are drawn from company announcements, regulators and trade press; links go to the sources.

• Jul 30, 2026: BMS reported Q2 sales of $2,485 million for Opdivo (down from $2,560 million), $261 million for Opdivo Qvantig (vs $30 million a year earlier) and $349 million for Opdualag (up 23%). It attributes the decline in IV Opdivo to US conversion to Qvantig. (BMS 10-Q)
• Jul 29, 2026: The European Patent Office Boards of Appeal revoked BMS patent EP 3 288 980 because its “nivolumab monotherapy” claims went beyond the application as filed. A related patent had been revoked earlier, in 2023, and the basic patent was upheld in amended form with SPC protection to the end of 2030. (JUVE Patent)
• Mar 20, 2026: FDA approved Opdivo with AVD for previously untreated stage III/IV classical Hodgkin lymphoma in adults and children 12 and older (SWOG S1826: HR 0.42 for progression or death). (BMS)
• Jun 2025: BMS and BioNTech announced a global partnership on pumitamig (BNT327, a PD-L1/VEGF-A bispecific): $1.5 billion upfront and up to about $11.1 billion in total potential value. ASCO 2026 Phase 2 data showed response rates of 57.1% (non-squamous) and 68.4% (squamous) in 40 evaluable patients. (DCAT)
• Late May 2025: The European Commission approved subcutaneous nivolumab across several adult solid tumors, based on CheckMate-67T. (Pharmaceutical Technology)
• Apr 2025: FDA approved Opdivo with Yervoy for first-line MSI-H/dMMR colorectal cancer on April 8 (CheckMate-8HW) and for first-line liver cancer, announced by BMS April 11 (CheckMate-9DW: median OS 23.7 vs 20.6 months, HR 0.79). (Pharmaceutical Technology)
• Feb 17, 2025: BMS announced that RELATIVITY-098, adjuvant Opdualag vs Opdivo in resected stage III-IV melanoma, missed its primary endpoint; two-year recurrence-free survival was 62% vs 63.6%. (Medthority)
• Dec 27, 2024: FDA approved Opdivo Qvantig (nivolumab with hyaluronidase) for most adult solid-tumor indications of IV Opdivo, the first subcutaneous PD-1 inhibitor. (PearceIP)

Upcoming catalysts

• Oct 23-27, 2026: ESMO Congress, Madrid.
• Ongoing: RELATIVITY-1093 (Opdualag plus chemotherapy vs pembrolizumab plus chemotherapy in non-squamous NSCLC with PD-L1 1-49%); no readout date has been disclosed.
• Ongoing: the pumitamig Phase 3 program in NSCLC; no readout dates disclosed.
• Ongoing: further EPO opposition decisions and Amgen’s ABP 206 biosimilar trial.

Bottom line

Nivolumab’s future rests on combinations, the early-stage setting and formulation convenience. Its contribution to the field includes proving that dual checkpoint blockade can work, even where adding agents has not always been successful.

Want this kind of analysis for the cancer areas you compete in? Request information and we will share sample deliverables.

This article is for informational and competitive-intelligence purposes only and is not medical advice. Approvals, labels and trial results change; verify details against current prescribing information and primary sources.